designer491 / iStockphoto.com
The Federal Trade Commission (FTC) is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FTC, Federal Trade Commission, generics, Amneal Pharmaceuticals, Impax Laboratories, mergers and acquisitions, M&S, anticompetitive